FOLH1 and prostate carcinoma: Structure-activity relationships enabled design of equipotent analogues containing a linker coupled with peptides that are substrates for either prostate specific antigen (PSA) or prostate specific membrane antigen (PSMA), which enables specific targeting of the prodrug to prostate cancer cells and hepatocellular carcinoma cells.